title: Intravenous treatment of hyperhomocysteinemia in patients on chronic hemodialysis--a pilot study.
abstract: BACKGROUND
  Treatment of hyperhomocysteinemia in patients with end-stage renal disease (ESRD) can be performed with the oral application of vitamins. However, this therapy rarely normalizes total homocysteine (tHcy) levels. Frequently, a rebound is observed after the end of treatment. Currently, no data are available about intravenous combination therapy with folic acid, pyridoxine (B6), and cyanocobalamin (B12).
  
  
  METHODS
  We conducted a prospective pilot study comprising 13 patients on chronic hemodialysis treatment (63.7+/-4.9 years; 6 female, 7 male) for 27 weeks. The patients received 10 mg folic acid and 100 mg pyridoxine intravenously (IV) after each dialysis plus 1000 microg vitamin B12 IV once a week for 9 weeks. Between weeks 10 and 18 the patients received 10 mg folic acid, 100 mg vitamin B6 once a week, and 1000 microg vitamin B12 bimonthly IV.
  
  
  RESULTS
  The therapy regimen decreased tHcy concentration (baseline: 30.5+/-2.2 micromol/L) significantly to 17.4+/-1.2 micromol/L, 15.6+/-1.0 micromol/L, and 16.4+/-0.1 micromol/L after 3, 6, and 9 weeks, respectively (p<0.01 vs. baseline concentration). The maximum reduction (-47.5+/-3.3%) of tHcy concentration was measured after 6 weeks of therapy. During the following maintenance therapy, tHcy-levels did not increase and no rebound of tHcy was detected during follow-up (week 27:16.5+/-1.97 micromol/L).
  
  
  CONCLUSIONS
  The concept of a short, high-dose induction therapy with intravenous folic acid, pyridoxine, cyanocobalamin, and a subsequent low-dose maintenance regimen is effective in the treatment of hyperhomocysteinemia in patients with ESRD.
authors.affiliation: Department of Internal Medicine I, University of Bonn, Bonn, Germany. u.poege@uni-bonn.de
authors.forename: Uwe
authors.initials: U
authors.lastname: Pöge
authors.forename: M
authors.initials: M
authors.lastname: Look
authors.forename: T
authors.initials: T
authors.lastname: Gerhardt
authors.forename: H U
authors.initials: HU
authors.lastname: Klehr
authors.forename: T
authors.initials: T
authors.lastname: Sauerbruch
authors.forename: R P
authors.initials: RP
authors.lastname: Woitas
mesh_terms: D000368:Aged; D003131:Combined Modality Therapy; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D005260:Female; D005492:Folic Acid / Q000008:administration & dosage*; D005500:Follow-Up Studies; D006801:Humans; D020138:Hyperhomocysteinemia / Q000188:drug therapy* / Q000209:etiology; D007262:Infusions, Intravenous; D007676:Kidney Failure, Chronic / Q000150:complications* / Q000175:diagnosis / Q000628:therapy; D007677:Kidney Function Tests; D008297:Male; D008875:Middle Aged; D010531:Peritoneal Dialysis, Continuous Ambulatory / Q000379:methods*; D010865:Pilot Projects; D011336:Probability; D011446:Prospective Studies; D011736:Pyridoxine / Q000008:administration & dosage*; D018570:Risk Assessment; D012720:Severity of Illness Index; D016896:Treatment Outcome; D014805:Vitamin B 12 / Q000008:administration & dosage*
chemical_list: D005492:Folic Acid; D011736:Pyridoxine; D014805:Vitamin B 12